Who is eligible for clinical trial NCT06907251?

Participants must meet the protocol's inclusion criteria for COVID - 19. The stated age range is 18 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT06907251 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-06-30

Dapagliflozin for Long COVID Syndrome (NCT06907251)

🟡 Not Yet Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Ottawa Heart Institute Research Corporation

🩺 Plain-English Summary (8th-Grade Level)

This is a randomized, placebo-controlled study. Patients with long COVID will be randomized to receive dapagliflozin or placebo for 12 months.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (4 items) and avoid the listed exclusions (8 items).

Location: University of Ottawa Heart Institute — Ottawa, Ontario

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

18 years of age or older and willing and able to provide informed consent
Patients with a history of positive COVID-19 test (polymerase chain reaction or rapid test) or have been diagnosed with COVID-19 by a health care provider.
New or persistent symptoms at least 12 weeks from infection and present for at least 8 weeks that is not explained by an alternative diagnosis (64).
Women of childbearing potential (WOCBP) who, if sexually active, are willing to use to use at least one highly effective methods of contraception throughout the study.

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
History of diabetes
Prior heart failure
Weight loss treatment with glucagon-like peptide-1 receptor agonists (e.g. liraglutide, semaglutide)
Pregnancy or planned pregnancy in the next 12 months. We will ask WOCBP about the possibility of pregnancy at the time of screening and if so, then pregnancy testing will be offered. If testing is declined in this instance, then they will be excluded from the study.
Women who are breastfeeding
Severe renal impairment (eGFR\<30mL/min1.73m2)
Known history of allergy or hypersensitivity to dapagliflozin Exclusion for optional MRI portion of the protocol: \- Any contraindication to MRI

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

University of Ottawa Heart Institute — Ottawa, Ontario

📞 Contact the Study Coordinator

Phone: (613) 696-7000

Email: dpaterson@ottawaheart.ca

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

Explore by condition: All COVID - 19 clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗